B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals.

Medically reviewed by Patricia Mikula, PharmD The majority of children and adults who receive the hepatitis B (hep B) virus ...

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids.

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body ...

Earnings Call Insights: Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving ...

Its flagship product, Heplisav-B, is a hepatitis B vaccine for adults that offers full protection with a two-dose regimen, unlike traditional three-dose vaccines. The company uses its proprietary ...

The company's primary asset is a hepatitis B vaccine called Heplisav-B that continues to gain market share in a growing market due to its 'best of breed' combination of efficacy and compliance ...

The investor says the company’s acquisition plan is "empire-building"; the company says the investor is employing a "strip-mining strategy." An East Bay vaccine maker fired back at an East Coast ...

The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant ...

Deep Track founder David Kroin criticized Dynavax for failing to concentrate on building up its vaccine Heplisav and chasing after "a misguided 'empire-building' exercise." "We remain deeply ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected ...